ARS Pharmaceuticals, Inc. (SPRY)
$4.05-3.11%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $402M
- Beta
- 0.88
- P/E (TTM)
- -1.86
- Short % float
- 32.85%
- Days to cover
- 16.1
- SI change
- -8.2%
- 1W
- -5.81%
- 1M
- -10.00%
- vs SPY 1W
- -5.68%
- vs SPY 1M
- -12.51%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 0
- GROWTH
- 27
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-154.0%
REV YoY-
ROE-256.7%
EPS YoY-
ROA-86.3%
GROSS74
OP-185
NET-184
[VALUATION]
P/E TTM-1.86
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B32.15
P/FCF-
EV/EBITDA-2.73
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E1371.51
ALTMAN Z-
CURR RATIO3.48
ND/EBITDA-
BETA0.88
Company news
FAQ
- What is LOPJLB’s current signal on SPRY?
- LOPJLB’s latest quantitative signal on ARS Pharmaceuticals, Inc. (SPRY) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is SPRY in?
- ARS Pharmaceuticals, Inc. (SPRY) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does ARS Pharmaceuticals, Inc. (SPRY) do?
- ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intran…